Edwards Q1 sales +16.7% to $1.65B; raises FY guidance on TAVR strength

Edwards Lifesciences Corp

2026-Q1 EPS reported $0.66 revenue$1,648,600,000

Q1 sales $1.65B, +16.7% YoY; constant currency +12.7%; TAVR sales $1.20B, +14.4%.
GAAP EPS $0.66; adjusted EPS $0.78, beating consensus; gross margin 78.0%.
Raises FY 2026 constant currency sales growth guidance to 9-11% (from 8-10%); new TAVR growth 7-9%.
Raises FY adjusted EPS guidance to $2.95-$3.05 from $2.90-$3.05; sees Q2 sales $1.66-$1.74B.
Completed $500M ASR; $1.5B remaining buyback authorization; cash $2.4B, debt $0.6B.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Edwards Lifesciences Corp updated its first quarter of 2026 guidance (raised).

Period: first quarter of 2026
Guidance: raised
Result: reported results

Exact text from the filing

issued a press release setting forth Edwards' financial results for the first quarter of 2026.

View on SEC.gov

1341 earnings releases filed in the last 30 days. Browse all earnings releases →

Edwards Lifesciences Corp filing history →

Source: SEC EDGAR

accession 0001099800-26-000021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.